RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA

Similar documents
Targeted Radioimmunotherapy for Lymphoma

Patterns of Care in Medical Oncology. Follicular Lymphoma

SEQUENCING FOLLICULAR LYMPHOMA

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL

Update: Non-Hodgkin s Lymphoma

New Targets and Treatments for Follicular Lymphoma

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma

12 th Annual Hematology & Breast Cancer Update Update in Lymphoma

Mathias J Rummel, MD, PhD

Digital Washington University School of Medicine. Russell Schilder Fox Chase Comprehensive Cancer Center. Arturo Molina Biogen Idec

Managing patients with relapsed follicular lymphoma. Case

eastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning

Open questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland

The case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.

How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma

Ibritumomab Tiuxetan in Lymphoma: A Clinical Practice Guideline

THE USE OF IBRITUMOMAB AS CONSOLIDATION THERAPY AFTER REMISSION INDUCTION IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA

DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA

Emerging targeted therapies for follicular lymphoma A future without chemotherapy

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

Jonathan W Friedberg, MD, MMSc

Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009

Updates in the Treatment of Non-Hodgkin Lymphoma: ASH Topics

Rituximab in the Treatment of NHL:

Betalutin for the treatment of recurrent indolent NHL: new insights. Dr. Arne Kolstad 22 November 2017

Betalutin : a modern approach to treating NHL patients. Arne Kolstad Oslo University Hospital Norway

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre

Disclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida

FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?

Scottish Medicines Consortium

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

How I treat High-risk follicular lymphoma

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012

Betalutin, a novel CD37-targeted radioimmunotherapy for NHL. Arne Kolstad Oslo University Hospital 2 October 2018

Betalutin (177Lu-Lilotomab)

Tiuxetan ( 90 Y-IT) as a consolidation

Notification to Implement Issued by pcodr: December 14, 2012

ICML BETALUTIN LYMRIT STUDY UPDATE JUNE 14 TH, 2017

TRANSPARENCY COMMITTEE OPINION. 8 November 2006

MMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE

Radiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York

ASH POSTER: LYMRIT UPDATE

Il trattamento del Linfoma Follicolare in prima linea

Disclosures WOJCIECH JURCZAK

ZEVALIN (ibritumomab tiuxetan) Information for Authorized Users and Administration Facilities

Radioimmunotherapy for lymphoma analysis of clinical trials and treatment algorithms

Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:

Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!

Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta

Address correspondence to: Brad S. Kahl, MD 1111 Highland Avenue, 4059 WIMR Madison, WI

CME Information LEARNING OBJECTIVES

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe

CME Information. Y-ibritumomab tiuxetan to that of rituximab maintenance for patients with newly diagnosed follicular lymphoma (FL).

PET-imaging: when can it be used to direct lymphoma treatment?

PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma

Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial

Betalu'n ( 177 Lu-HH1)

Bendamustine for relapsed follicular lymphoma refractory to rituximab

Panel Discussion/References

DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA

Interim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience

Supplementary Appendix to manuscript submitted by Trappe, R.U. et al:

The case for maintenance rituximab in FL

Nuove opportunità di cura. Stefano Sacchi, Modena

Traitement de première ligne du lymphome folliculaire. F Morschhauser DES, 17 novembre,2017 Centre Hospitalier Universitaire de Lille, France

Challenges in the Treatment of Follicular Lymphoma

Media Release. Basel, 5 December 2016

New developments in the treatment of FL. Massimo Federico University of Modena and Reggio Emilia Italy

Chapter 5. M.J. Wondergem 1, J.M. Zijlstra 1, M. de Rooij 1, O.J. Visser 1, P.C. Huijgens 1, S. Zweegman 1

Bendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service

Lymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL):

VENETOCLAX (ABT 199) Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth

Follicular Lymphoma: Updates and novel immune therapies

LYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France

CAR-T cell therapy pros and cons

Lymphomas in Prof Paul Ruff Division of Medical Oncology

Overview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC

Bcl-2 inhibition in NHL. Jonathan W. Friedberg M.D., M.M.Sc.

Non-Hodgkin lymphoma

Expanding the Horizons )N 3UPPORTIVE #ARE /NCOLOGY. Communiqué from ICML 2008

CLINICAL STUDY PROTOCOL PRIMA. Primary Rituximab and Maintenance

Follicular Lymphoma 2016:

Clinical Overview: MRD in CLL. Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel

Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens

Dr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation

Radioimmunotherapy for B-Cell Non-Hodgkin Lymphomas

Update: New Treatment Modalities

NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

Firenze, settembre 2017 Novità dall EHA LINFOMI Umberto Vitolo

Radiotherapy in aggressive lymphomas. Umberto Ricardi

MED B Form CLL. Johannes Schetelig. London 09/April/

Experimental Hematology & Oncology

*Jagiellonian University, Kraków, Poland

Update on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question?

Angioimmunoblastic T-cell lymphoma: nobody knows what to do...

Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents

Outcome of DLBCL patients over 80 years: A retrospective survey from 4 Institutions

Options in Mantle Cell Lymphoma Therapy

Transcription:

RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007

Zevalin 1st-line in FL (1) Treatment regimen: 1 Day 8 6 12 Month 18 24 90 Y-ibritumomab tiuxetan, day 8: 15 MBq/kg BW, platelet count 150.000/mm³, 11 MBq/kg BW, platelet count >100.000/mm³ and <150.000/mm³ (max. 1 200 MBq) Rituximab 250 mg/m 2 day 1 and 8 Rituximab maintenance therapy 375 mg/m 2 /w x 4; q6 months for 2 years Multicentre phase II study. Interim analysis after 10 patients, planned 23 patients Median age 58 (40-82) years 50% stage IV Sweetenham et al. Blood 104(11):720a, abstr 2633 (2004)

Zevalin 1st-line in FL (2) Response rate (%) 100 80 60 40 20 0 100 ORR 62 CR Response rates (n=8): ORR: 100% CR: 62% Safety: 38% grade 3 cytopenia non-haematologic adverse events only grade I Sweetenham et al. Blood 104(11):720a, abstr 2633 (2004)

Zevalin as Consolidation after 1st-line Chemoimmunotherapy in FL (1) Week 1 2 3 4 5 11 16-18* 8 Rituximab 375 mg/m 2 i.v. R-CHOP or R-CVP (q3w, 3 cycles) Rituximab 250 mg/m 2 day 1 and 8 Zevalin 15 MBq/kg BW; *interval at least 5 weeks Shipley et al. Proc ASCO 23(16S):579s, abstr 6577 (2005)

Zevalin as Consolidation after 1stline Chemoimmunotherapy in FL (2) Study details Multicentre phase II study (Follow-up: median 24 months) Age median (range) Ann Arbor stage II Ann Arbor stage III Ann Arbor stage IV Chemoimmunotherapy with R-CHOP Chemoimmunotherapy with R-CVP Complete response (CR and CRu) after chemoimmunotherapy (n=40) after Zevalin (n=39) Progression free survival after 2 years n=42 (evaluable with respect to total therapy: n=39) 53 (33-82) years 12% 28% 60% 86% 14% 30% 66% 85% Shipley et al. Proc ASCO 23(16S):579s, abstr 6577 (2005)

Zevalin in 1st line with chemoimmunotherapy in follicular NHL (3) Response rates after chemoimmunotherapy and after Zevalin Progression free survival 100 70 PR 31 100 CR/CRu Response rate (%) 80 60 40 20 30 66 Progression free survival (%) 80 60 40 20 0 after chemoimmunotherapy after Zevalin 0 0 6 12 18 24 30 36 Months Shipley et al. Proc ASCO 23(16S):579s, abstr 6577 (2005)

Zevalin as Consolidation after 1stline Chemoimmunotherapy in FL (4) 16 patients with previously untreated follicular NHL were included in a phase II study in Pittsburgh. Treatment: 3 x R-CHOP, followed by Zevalin (w +4) and 4 x rituximab (w +5 till +9) Median age 59.4 years, 14/16 stage III/IV, 11/16 FLIPI intermediate or high risk Response (CR) following R-CHOP or Zevalin (n=16): CT: 38.5% 81% PET-negative: 53.3% 100% PET-CT: 26.7% 80% DeMonaco NA et al. J Clin Oncol 24(Suppl 18):444s, abstr 7589 (2006)

Zevalin in 1st line with chemoimmunotherapy in follicular NHL (5) 100 80 Response rates according to CT, PET or PET-CT after R-CHOP or 12 weeks after consolidation with Zevalin PR CR Response rate (%) 60 40 20 0 R-CHOP Zevalin CT R-CHOP Zevalin PET DeMonaco NA et al. Blood 106 (11):689A, abstr 2449 (2005) R-CHOP Zevalin PET _ CT

EU/Canada: FIT (First-line Indolent Trial) Phase III consolidation study Newly diagnosed follicular NHL Stage III - IV Remission induction chemotherapy* NR PD Start of study CR /PR No inclusion 90 Y- ibritumomab tiuxetan No further Treatment *Left to the discretion of the treating physician, e.g. CLB, CHOP, CVP, fludarabine etc. (incl. rituximab after last protocol ammendment) This study included MRD monitoring and QoL assessment

EU/Canada: FIT (First-line Indolent Trial) Country Number of active study centers No further Number of patients treatment 90 Y-I T TOTAL Belgium 5 19 20 39 Canada 4 13 13 26 Denmark 2 5 6 11 France 14 46 41 87 Germany 9 10 16 26 Italy 11 30 30 60 Norway 2 7 6 13 Portugal 4 11 7 18 Spain 6 16 15 31 Sweden 1 4 2 6 Switzerland 3 4 10 14 NL 10 21 21 42 UK 5 20 21 41 Total 76 206 208 414 Primary objective To detect a prolongation of the progression-free survival period by 50% (increase of PFS from 30% to 45% at 4 years) Data will be presented at ASH 2007

Phase II study of sequential FM and 90 YIbritumomab of untreated indolent (non-follicular) NHL patients FM q28 x 6 cycles 90 Y Ibritumomab tiuxetan 6-10 weeks after FM Enrolled 26 patients Restage 4-6 weeks after FM

Main patients characteristics (n=26) Median age (range) 61(45-82) Sex male/female 13/13 Stage III 4 Stage IV 22 (85 %) Bone marrow involvement 20 (80%) Extranodal involvement 6 (23%) Bulky disease 2 (8%) Histology Marginal zone Lymphoplasmacytic lymphoma Small lymphocytic lymphoma 10 (40%) 8 (30%) 8 (30%)

Clinical response after FM (n=26) CR 13 (50 %) PR 8 (30%) PD 5 (20%)

Clinical response after Zevalin (n=20) After FM After Zevalin CR 13 (65 %) 20 (100 %) PR 7 (35 %) /

Duration of hematologic toxicity Variable Baseline Nadir (range) ANC, cells/mm 3 2700 (1500-6500) 700 (210-2000) Days from Baseline to Nadir 41 (30-51) Median duration for patients with grade 3 or 4 Nadir (days) 30 (17-56) Platelets, cells/mm 3 186 (150-500) 23 (11-120) 35 (29-50) 36 (20-104) Hemoglobin, g/dl 13.4 (12-15.9) 9 (7.2-14) 45 (30-51) 38 (25-104)

Hematological toxicity after Zevalin (n=20) Anemia grade III-IV 7 (27 %) Neutropenia grade III-IV 11 (42 %) Thrombocytopenia grade III-IV 16 (61 %) Patients who required transfusion 6 (22 %) Antibiotic 5 Febrile neutropenia 1(4%) Hospitalization due to FN 1

Phase II study of sequential FM (oral fludarabine and mitoxantrone) and 90 YIbritumomab of untreated follicular NHL patients (FLUMIZ) FM q28 x 6 cycles 90 Y Ibritumomab tiuxetan 6-10 weeks after FM Enrolled 61 patients Restage 4-6 weeks after FM

Main patients characteristics (n=61) Median age (range) 54 (30-72) Male/Female 25/37 Stage II 6 (10%) Stage III 20 (32%) Stage IV 36 (58%) Bone marrow involvement 31 (51%) Extranodal involvement 5 (8%) Bulky disease 15 (25%)

Clinical response after FM (n=61) CR 37 (61%) CRu 6 (10%) PR 17 (27%) PD 1 (2%)

Clinical response after Zevalin (n=57) After FM After Zevalin CR 43 55 (96%) PR 17 2 (4%)

CR 43 PR 17 12 pts (70%) 3 pts (18%) Not eligible Zevalin CR 55 43 pts PR 2 2 pts (12%)

Bcl-2 monitoring Patients evaluable for Bcl-2 23 Bcl-2 + before Zevalin 18 Molecular CR 14 (78%) Molecular relapse 2/14 (11%) 2/9 (22%) * Median follow-up for molecular analysis 12 months * These patients are alive, with complete response

Hematological toxicity after Zevalin Anemia grade III-IV 13 (28 %) Neutropenia grade III-IV 30 (65 %) Thrombocytopenia grade III-IV 36 (78 %) Patients who required transfusion 21 (46 %) Antibiotic 20 (43%) Febrile neutropenia 5 (11 %) Hospitalization due to FN 2 (4%) Infections 7 (15%)

Duration of hematologic toxicity Variable Baseline Nadir (range) ANC, cells/mm 3 2700 (1230-6240) 644 (20-2418) Days from Baseline to Nadir 42 (31-158) Median duration for patients with grade 3 or 4 Nadir (days) 30 (3-105) Platelets, cells/mm 3 175 (120-341) 23 (2-133) 35 (23-61) 35 (8-116) Hemoglobin, g/dl 13.7 (11.5-16.5) 9.7 (6.3-14.7) 53 (31-60) 42 (26-121)

R-CHOP Followed by 90 Y Ibritumomab Tiuxetan in DLBCL (ECOG-E3402): Study Schema R-CHOP 2 cycles CR R-CHOP 2 cycles PR, CRu, or SD R-CHOP 4 cycles R E R E G I S T E R Stable or progressive disease off-study 90 Y Ibritumomab tiuxetan therapeutic regimen R E G I S T E R CT or CT+/PET Observation CT+/PET+ IFRT 30 Gy Study chair: Thomas Witzig. National Cancer Institute. Available at http://www.cancer.gov/. Protocol ID: ECOG-E3402. CT, computed tomography; PET, positron emission tomography

Phase II Study of Sequential R-CHOP and 90 Y Ibritumomab for Elderly High-Risk Patients with Untreated DLBCL R-CHOP q 21 6 cycles + darbepoetin 90 Y Ibritumomab tiuxetan 6 9 weeks after R-CHOP Re-stage between cycle 4 and 5 Restage 4 5 weeks after R-CHOP Restage 12 13 weeks after RIT Hamlin et al. Blood.. 2005; 106 (11). Abstract 926. Poster Session Saturday.

Randomized Trial of 90 Y Ibritumomab Tiuxetan vs Observation After Front-line CHOP-R Randomization (start of the trial) Patients with untreated stage II-IV DLBCL, age 60 CHOP + Rituximab CR/CRu 90 Y Ibritumomab tiuxetan (0.4 mci/kg) Observation Primary end point: Overall survival Study chair: Franck Morschhauser

Phase II (Hovon) Study in DLBCL: 90 Y Ibritumomab Tiuxetan Consolidation for Partial Responders Patients with untreated DLBCL Chemo* + Rituximab PR PET scan PET + or 90 Y ibritumomab tiuxetan (0.4 mci/kg) *CHOP or CHOP-like regimen Study chair: Ton Hagenbeek

Integrating 90 Y Ibritumomab Tiuxetan with Chemotherapy in DLBCL Rituximab Followed by 0.2 0.3 mci/kg 90 Y ibritumomab tiuxetan Rituximab Followed by 0.2 0.3 mci/kg 90 Y ibritumomab tiuxetan Week 0 3 6 9 12 15 CHOP-R CHOP-R CHOP-R CHOP-R Study chair: Tim Illidge

Z in localized 1st line Aggressive Lymphoma (SWOG-S0313, Miller) Regimen Standard Dose CHOP q21d x 3 3 wks Involved field radiotherapy 5d/wk for 4 5 wks 3 6 wks Zevalin Therapeutic Regimen Occurs over a period of 20-24 weeks Patients are followed up every 6 months for 2 years and then annually thereafter. R E S T A G E

Phase II study of sequential CHOP and 90 YIbritumomab of elderly untreated DLCBL patients: Bologna CHOP q21 x 6 cycles 90 Y Ibritumomab tiuxetan 6-10 weeks after CHOP Restage 4-6 weeks after CHOP Enrolled 20 patients

Patients characteristics (n=20) Histology Follicular grade 3 DLBCL 9 11 Median Age, yr (range) 68 (61-84) Stage II 6 (30 %) Stage III-IV 14 (70 %) Bone marrow involvement 5 (25 %) Extranodal involvement 7 (35 %) Bulky disease 2 (10 %) B symptoms 2 (10 %)

Hematological toxicity after Zevalin Anemia grade 3-4 1 Neutropenia grade 3-4 12 (60 %) Thrombocitopenia grade 3-4 7 (35 %) Nadir (median) Week 5 Median duration nadir 4 weeks Patients who required transfusion 2 (10 %) Antibiotic 5 (25 %) Febrile neutropenia 3 (15 %) Hospitalization due to FN 1

Clinical response after Zevalin After CHOP After Zevalin CR 15 (75 %) 19 (95 %) PR 5 (25 %) 1 (5 %)

Duration of hematologic toxicity Variable Baseline Nadir (range) ANC, cells/mm 3 3300 (1600-5460) 800 (255-3000) Days from Baseline to Nadir 39 (20-60) Median duration for patients with grade 3 or 4 Nadir (days) 32 (10-66) Platelets, cells/mm 3 217 (150-500) 42 (9-187) 35 (20-43) 22 (10-49) Hemoglobin, g/dl 13.5 (12-14.5) 11.8 (8.7-14.2) 43 (20-60) /

Untreated Elderly (> 60 years) DLBCL, stage II-IV, CD20+ (Bologna) Phase II: CHOP21-R x 4 + Zevalin Phase III:R CHOP21- R x 8 CHOP21- R x 4 + Zevalin